ANI Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

 ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®.

https://www.globenewswire.com/news-release/2025/01/02/3003434/0/en/ANI-Pharmaceuticals-Announces-the-FDA-Approval-and-Launch-of-Prucalopride-Tablets-with-180-Day-CGT-Exclusivity.html